Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Other Accumulated Expenses (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of Other Accumulated Expenses data on record, last reported at $296000.0 in Q1 2025.

  • For Q1 2025, Other Accumulated Expenses changed N/A year-over-year to $296000.0; the TTM value through Mar 2025 reached $296000.0, changed N/A, while the annual FY2024 figure was $289000.0, 17.96% up from the prior year.
  • Other Accumulated Expenses reached $296000.0 in Q1 2025 per CRVS's latest filing, up from $289000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $402000.0 in Q3 2024 and bottomed at $137000.0 in Q2 2023.
  • Average Other Accumulated Expenses over 4 years is $273250.0, with a median of $275500.0 recorded in 2023.
  • The widest YoY moves for Other Accumulated Expenses: up 53.44% in 2024, down 17.96% in 2024.
  • A 4-year view of Other Accumulated Expenses shows it stood at $176000.0 in 2022, then surged by 39.2% to $245000.0 in 2023, then rose by 17.96% to $289000.0 in 2024, then increased by 2.42% to $296000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $296000.0 in Q1 2025, $289000.0 in Q4 2024, and $402000.0 in Q3 2024.